The Second Mitochondria‐Derived Activator of Caspases Mimetic BI 891065 in Patients With Advanced Solid Tumors: Results From Two Phase I Studies

ABSTRACT Introduction BI 891065, a second mitochondria‐derived activator of caspases mimetic targets the inhibitor of apoptosis (IAP) family member cIAP1. We describe two first‐in‐human phase 1 trials assessing BI 891065 ± the anti‐programmed cell death protein‐1 (PD1) antibody, ezabenlimab, in adva...

Descrición completa

Detalles Bibliográficos

Principais autores:	Manish R. Patel, Erika P. Hamilton, Ben George, Gunther Kretschmar, Akiko Harada, Ralph Graeser, Anastasia Eleftheraki, Yoshifumi Tachibana, Noboru Yamamoto
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2025-12-01
Series:	Cancer Medicine
Assuntos:	checkpoint control clinical cancer research experimental therapeutics ezabenlimab IAP medical oncology
Acceso en liña:	https://doi.org/10.1002/cam4.71451
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!